Any serious consideration of ibogaine should begin with complete, accurate disclosure of medical conditions, medications, supplements, substance use, and prior adverse reactions. Omitting details can make it harder for a qualified clinician to identify concerns or advise on safer next steps.
Cardiac issues are especially important to understand. Ibogaine has been associated with changes to cardiac electrical activity, including QT interval concerns; the FDA discussion of drug-induced QT prolongation explains why this kind of effect can be clinically significant.
Screening may identify known contraindications or prompt further evaluation, but it cannot guarantee an outcome. Questions about testing, review of records, medication changes, and emergency planning should be met with clear limits rather than assurances.